Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A pre-existing diagnosis of ADPKD as defined in the protocol
Willing and able to comply with scheduled visits and other study procedures
Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening
Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73 square meter (m\^2)
You may not be if
History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
History of solid organ or bone marrow transplantation or nephrectomy
Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening
Clareo Health | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
